Navigation Links
Development of a therapeutic algorithm for optimal nosebleed management
Date:8/26/2013

Approximately 60 percent of people experience epistaxis, commonly known as nosebleed, at least once in their lifetime. Of those who experience nosebleed, six percent require medical treatment. A study in the September 2013 issue of OtolaryngologyHead and Neck Surgery, explores which nosebleed treatment options demonstrate the best outcomes.

"Although data exist on the efficacy of the different epistaxis management techniques, outcome comparisons between the modalities for both primary management as well as management of cases of recurrence are currently lacking," the authors stated.

The study analyzed various treatment outcomes of adult patients with epistaxis presenting to otolaryngologists at a tertiary care center between 2005 and 2011. The authors observed 147 patients (94 men and 53 women) who underwent cauterization, tamponade or nondissolvable packing, and/or proximal vascular control through embolization or surgical ligation. Treatment outcomes were then compared with the intent to derive an algorithm for optimal nosebleed management.

According to the study, nondissolvable packing demonstrated the highest rate of failure or recurrence (57.4 percent) for initial bleed management. Chemical cautery was significantly more successful in achieving lasting hemostasis for the first bleeding episode. The authors also found that the duration of the nondissolvable pack placement had no significant impact on nosebleed recurrence. Furthermore, among patients who failed initial management, those who next underwent more invasive procedures such as cautery, embolization or surgical ligation experienced better outcomes and shorter inpatient stays.

Because the subgroup analyses were limited in size for some of the treatment groups in this study, the authors urge caution when considering these findings.

Although most cases of nosebleed do not require medical intervention, those patients who do present to a tertiary care otolaryngologist and need medical attention require a systematic, stepwise approach to address their condition. This study demonstrates "good outcomes with initial treatment with chemical cautery and with procedures that achieve directed vascular control in patients who develop epistaxis recurrence."


'/>"/>

Contact: Lindsey Walter
newsroom@entnet.org
703-535-3762
American Academy of Otolaryngology - Head and Neck Surgery
Source:Eurekalert

Related medicine news :

1. 2 genetic deletions in human genome linked to the development of aggressive prostate cancer
2. Kudos for 3 NJIT Enterprise Development Center high-tech companies
3. 2 repressor genes identified as essential for placental development
4. Louisiana Tech University professor earns NSF Early Career Development grant
5. Advanced genetic screening method may speed vaccine development
6. New biospecimens management system in development
7. Developmental Woes Common in Siblings of Children With Autism
8. Mutations impair childhood growth and development by disrupting organization of chromosome pairs
9. Penn and Cornell researchers spearhead the development of new guidelines for veterinary CPR
10. Study sheds new light on role of genetic mutations in colon cancer development
11. The first day of development -- a window to successful pregnancy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... Florida (PRWEB) , ... February 05, 2016 , ... Steven ... event he has completed every year since it started in 2003. This year, he ... the attention of fellow runners and NBA team the Miami Heat. , This Sunday, ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... company's lighter, sleeker next generation LYNX VR Indoor Trainer with multi-rider capability to ... design and manufacturing not only reduce the weight of the unit, they also ...
(Date:2/5/2016)... ... 2016 , ... Successful recruitment and retention efforts, new collaborations ... have all marked the last 12 months at Roswell Park Cancer Institute (RPCI). ... oldest cancer center, Candace S. Johnson, PhD, outlined the many accomplishments of her ...
(Date:2/5/2016)... ... February 05, 2016 , ... The Muscular ... Louisiana Kitchen restaurants, launched the 14th annual “Appetite for a Cure” campaign on ... muscular dystrophy, ALS and related diseases that severely limit strength and mobility. ...
(Date:2/5/2016)... York, New York (PRWEB) , ... February 05, 2016 , ... ... life? The answer may be at the tips of your toes. Foot massage, whether ... as well as pure comfort and relaxation. The American Board of Multiple Specialties ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... 2016 Amgen (NASDAQ: AMGN ) will present ... Conference at 9:15 a.m. ET on Wednesday, Feb. 10, 2016, ... W. Meline , executive vice president and chief financial officer ... the presentation can be accessed from the Events Calendar on ... the webcast will also be available on Amgen,s website for ...
(Date:2/5/2016)... Feb. 5, 2016  ivWatch, a medical devices company, is ... Award granted by Governor Terry McAuliffe,s office. ivWatch ... February 25th at an event to be held at the ... award honors professionals and business that have made significant contributions ... Logo - http://photos.prnewswire.com/prnh/20160205/330117LOGO ...
(Date:2/5/2016)... MILTON, Ontario , Feb. 5, 2016  Aralez ... business combination of POZEN Inc. ("POZEN") and Tribute Pharmaceuticals Canada ... of POZEN and shareholders of Tribute. The combined company ... specialty pharmaceutical company with operations in Canada ... the United States . Under the terms ...
Breaking Medicine Technology: